<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>55</patient-age><report-id>PHHY2012DE004006</report-id><gender>female</gender><reactions><reaction>Diabetes mellitus type 2</reaction><reaction>MS relapse</reaction><reaction>Headache</reaction><reaction>Fever</reaction><reaction>Chills</reaction><reaction>Indurations after injection on abdomen/ indurations on the abdomen (partly encysted)</reaction><reaction>Induration and reddening after injection on abdomen</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EXTAVIA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>VERAHEXAL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>GABAPENTIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>MAGNESIUM VERLA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TORASEMIDE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Multiple sclerosis</indication><indication>Blood pressure</indication><indication>Pain</indication><indication>Muscle spasms</indication><indication>Fluid retention</indication></indications><patient-age>55</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Germany</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053108_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133617</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>4</safetyreportversion>
		<safetyreportid>PHHY2012DE004006</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-01-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-03</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012DE004006</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>55</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Injection site induration</patientepisodename>
				<patientmedicalcomment>Indurations present under treatment with Betaferon, either to a greater or lesser extent, the patien</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Arrhythmia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Blood pressure increased</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pain</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Muscle spasms</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Fluid retention</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Blood pressure</patientepisodename>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>BETAFERON</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>200108</patientdrugstartdate>
				<patientdrugenddateformat>102</patientdrugenddateformat>
				<patientdrugenddate>20090904</patientdrugenddate>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Diabetes mellitus type 2</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Type 2 diabetes mellitus</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Type 2 diabetes mellitus</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201201</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>MS relapse</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Multiple sclerosis relapse</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Multiple sclerosis relapse</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Headache</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Headache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Headache</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fever</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fever</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pyrexia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Chills</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chills</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Chills</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Indurations after injection on abdomen/ indurations on the abdomen (partly encysted)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site induration</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site induration</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Induration and reddening after injection on abdomen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site redness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site erythema</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Nuclear magnetic resonance imaging</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EXTAVIA</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>BLA 125290</drugauthorizationnumb>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="012"/>
				<drugdosagetext>1 ml, QOD (every other day)</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution For Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2009-09-04</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>INTERFERON BETA-1B</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chills</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chills</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site induration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site induration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Multiple sclerosis relapse</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Multiple sclerosis relapse</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Type 2 diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Type 2 diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>VERAHEXAL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.5 DF, BID (120 at 1/2-0-1/2-0 per day)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood pressure</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VERAPAMIL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>GABAPENTIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.5 DF, QD (600 at 0-0-0-1/2 per day)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GABAPENTIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>MAGNESIUM VERLA</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>2 DF, QD (0-0-0-2 per day)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Muscle spasms</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MAGNESIUM CITRATE, MAGNESIUM GLUTAMATE, MAGNESIUM NICOTINATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TORASEMIDE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QD (0-0-0-1 per day)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Fluid retention</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TORASEMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012DE004006, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via marketing program Extracare G (DE MS11-033EXTRACAR, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor </Semaphore>Dr. Scharm) on 05 Jan 2012 with follow up report received from a <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 06 Jun 2012. Follow up report received from a <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 29 Aug 2012 with follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via the EXTRACARE G Service Center (DE MS11-033EXTRACAR, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor </Semaphore>Dr. Scharm) on 24 Oct 2012 with follow up report received from the <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via the EXTRACARE G Service Center (DE MS11-033EXTRACAR, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor </Semaphore>Dr. Scharm) on 03 Dec 2012: This case refers to 55-year old female patient (Patient ID: 1368). The patient injected Betaferon (<Semaphore x="735118" class="Medicine" value="interferon beta-1b" score="0.93" ID="281308"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.74" ID="268564">interferon beta </Semaphore>1b</Semaphore>) from Aug 2001 until switch to <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>on 04 Sep 2009. The patientâ€™s historical condition included <Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">indurations </Semaphore>present under <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Betaferon, either to a <Semaphore x="1995141" class="AnatomicStructure" value="Greater Curvature of the Stomach" score="1.00" ID="C12262">greater </Semaphore>or lesser extent, the patient injected predominantly into the <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>, <Semaphore x="1875899" class="Disease or Finding" value="Electrical Exposure" score="1.00" ID="C45407">current </Semaphore>condition <Semaphore x="2758290" class="MedDRA LLT" value="Arrhythmia" score="1.00" ID="10003119">cardiac arrhythmia </Semaphore>and <Semaphore x="2815617" class="MedDRA LLT" value="Blood pressure increased" score="1.00" ID="10005750">increased blood pressure</Semaphore>. Concomitant medication included Verahexal 120 (<Semaphore x="1325273" class="Medicine" value="Verapamil hydrochloride" score="0.49" ID="241442">verapamil hydrochloride</Semaphore>) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">blood pressure </Semaphore>at a dose 1/2-0-1/2-0 per day, <Semaphore x="608883" class="Medicine" value="gabapentin" score="0.49" ID="251588">gabapentin </Semaphore>600 <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>at a dose 0-0-0-1/2 per day, <Semaphore x="2812633" class="MedDRA LLT" value="Blood magnesium" score="1.00" ID="10005651">Magnesium </Semaphore>Verla (<Semaphore x="817890" class="Medicine" value="magnesium citrate" score="0.49" ID="269930"><Semaphore x="2812633" class="MedDRA LLT" value="Blood magnesium" score="1.00" ID="10005651">magnesium </Semaphore>citrate</Semaphore>, <Semaphore x="2812633" class="MedDRA LLT" value="Blood magnesium" score="1.00" ID="10005651">magnesium </Semaphore><Semaphore x="1988751" class="Procedure" value="Glutamate Measurement" score="1.00" ID="C74739">glutamate</Semaphore>, <Semaphore x="2812633" class="MedDRA LLT" value="Blood magnesium" score="1.00" ID="10005651">magnesium </Semaphore>nicotinate) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="2102792" class="Disease or Finding" value="Leg Cramp" score="1.00" ID="C34762">cramps in the legs </Semaphore>at a dose 0-0-0-2 per day, vitamin complex <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>at a dose 1-0-1-0 per day, Ibuhexal 400 mg (<Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.49" ID="271165">ibuprofen</Semaphore>) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>at a dose 0-0-0-1 per day, <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">torasemide </Semaphore>20 mg <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="2955345" class="MedDRA LLT" value="Fluid retention" score="1.00" ID="10016807"><Semaphore x="1361751" class="Medicine" value="Water" score="0.49" ID="196879">water </Semaphore>retention </Semaphore>at a dose 0-0-0-1 per day and all for a long time. The patient received <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>250 mcg/ml (<Semaphore x="735118" class="Medicine" value="interferon beta-1b" score="0.93" ID="281308"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.74" ID="268564">interferon beta </Semaphore>1b</Semaphore>) subcutaneous for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis </Semaphore>(<Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS</Semaphore>) from 04 Sep 2009 at a dose of 1 ml every other day. Since long time (unspecified date), the patient was developed <Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">induration </Semaphore>and reddening after <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>on <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>. On 25 Jan 2012, the patient was hospitalized for the events, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">fever, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">chills </Semaphore></Semaphore>and <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache</Semaphore>. An MRT (magnetic resonance <Semaphore x="1804944" class="Procedure" value="Computed Tomography" score="1.00" ID="C17204">tomography</Semaphore>) was performed and <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapse </Semaphore>was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>which was treated with <Semaphore x="410220" class="Medicine" value="Cortisone" score="0.74" ID="243016">cortisone </Semaphore>at a dose of 250 mg five times daily. Approximately Jan 2012 (unspecified date)<Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">, <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus type 2 </Semaphore>was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed</Semaphore>, </Semaphore>which was treated with <Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.87" ID="279450">metformin </Semaphore>at a dose of 500 mg 2 times daily and <Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.87" ID="279450">metformin </Semaphore>1000 <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>at 1/2-0-1/2-0 per day. The <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>informed that, the patient injected only in her <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen </Semaphore>area. The <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>reported that the patient <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.58" ID="C91103">was doing well </Semaphore>again and that her <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore><Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.58" ID="C91103">was well </Semaphore><Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled</Semaphore>. The patient was <Semaphore x="1670603" class="Procedure" value="CAM Exercise Therapy" score="1.00" ID="C64896">exercising </Semaphore>and all had worked well. The case was assessed as serious (<Semaphore x="2032443" class="Disease or Finding" value="Hospitalization Event" score="1.00" ID="C80481"><Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>) for events </Semaphore><Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="3225462" class="MedDRA LLT" value="Relapsing fever" score="1.00" ID="10038300"><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapse</Semaphore>, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">fever</Semaphore></Semaphore>
    <Semaphore x="3217249" class="MedDRA LLT" value="Pyrexia" score="1.00" ID="10037660">
     <Semaphore x="1932723" class="Disease or Finding" value="Fever Chills" score="1.00" ID="C26921">
      <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">chills</Semaphore></Semaphore></Semaphore></Semaphore>, <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus type 2 </Semaphore>and non serious for events <Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">indurations </Semaphore>on the <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen </Semaphore>and reddening on the <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>. The patient continued <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia</Semaphore>. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="3225462" class="MedDRA LLT" value="Relapsing fever" score="1.00" ID="10038300"><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapse</Semaphore>, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">fever</Semaphore></Semaphore>
    <Semaphore x="3217249" class="MedDRA LLT" value="Pyrexia" score="1.00" ID="10037660">
     <Semaphore x="1932723" class="Disease or Finding" value="Fever Chills" score="1.00" ID="C26921">
      <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">chills</Semaphore></Semaphore></Semaphore></Semaphore>, <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus type 2 </Semaphore>was reported as <Semaphore x="1803876" class="Disease or Finding" value="Complete Recovery" score="1.00" ID="C82467">complete recovery </Semaphore>and for rest of the events it was condition <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged</Semaphore>. The causality was reported as suspected (certain) for the event <Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">induration </Semaphore>after <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>on <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>, reddening on the <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen </Semaphore>and was not reported for all the other events.Follow up report received from a <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 06 Jun 2012: Action taken with <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>(ongoing), added <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>(<Semaphore x="410220" class="Medicine" value="Cortisone" score="0.74" ID="243016">cortisone</Semaphore>, <Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.87" ID="279450">metformin</Semaphore>), added new events and their clinical course (<Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">fever, <Semaphore x="1771273" class="Disease or Finding" value="Chills" score="1.00" ID="C35143">chills</Semaphore></Semaphore><Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">, <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache</Semaphore><Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">, <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus type 2</Semaphore></Semaphore>, </Semaphore><Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapse</Semaphore>) and updated <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">induration </Semaphore>after <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>on <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen </Semaphore>(condition <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged</Semaphore>).Follow up report received from a <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 29 Aug 2012: <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">Nurse </Semaphore>comment, event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>(<Semaphore x="3031881" class="MedDRA LLT" value="Induration" score="1.00" ID="10060708">induration </Semaphore>after <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>on <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>) and narrative was updated.Follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via the EXTRACARE G Service Center (DE MS11-033EXTRACAR, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor </Semaphore>Dr. Scharm) on 24 Oct 2012: Updated <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event, causality, action taken.Follow up report received from the <Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore><Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via the EXTRACARE G Service Center (DE MS11-033EXTRACAR, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor </Semaphore>Dr. Scharm) on 03 Dec 2012: Updated medical history, concomitant medications and narrative.</narrativeincludeclinical>
				<sendercomment>Review of reported data does not allow for a proper causality assessement for the event Type 2 diabetes mellitus.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>